FDA rule aims to boost quality of safety data from drug trials

09/28/2010 | Wall Street Journal, The

The FDA issued a rule that requires companies testing experimental drugs or medical products to inform the agency within 15 days about serious risks and adverse reactions that arise during clinical studies. The measure, which takes effect March 28, "will expedite FDA's review of critical safety information" and "will better protect people who are enrolled in clinical trials," an FDA official said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Chief Executive Officer
UCare Minnesota
Minneapolis, MN